MedTrace Logo

Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients

NCT02466373 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-07-30

No results posted yet for this study

Summary

This study is developed for assessing the pharmacodynamic and pharmacokinetic properties of intravenous (IV) clonidine in critically ill patients on the ICU, and to estimate the optimal dosing strategy for IV clonidine.

Conditions

  • Delirium
  • Critical Illness

Interventions

DRUG

Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

clonidine intravenous

Sponsors & Collaborators

  • Deventer Ziekenhuis

    lead OTHER

Principal Investigators

  • Huub Oever v/d · Deventer Ziekenhuis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-04-05
Completion
2018-04-05

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02466373 on ClinicalTrials.gov